Regorafenib: start low and go slow

Targeted Oncology

Volumn 10, Issue 3, 2015, Pages 445-447

  Tabchi, S ^a   Ghosn, M ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Adverse events; mCRC; Regorafenib

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REGORAFENIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ARTICLE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTRACELLULAR SIGNALING; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; COLORECTAL NEOPLASMS; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; GASTROINTESTINAL TRACT; METASTASIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL TRACT; HUMANS; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84940898385     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0352-7     Document Type: Article

References (10)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer, version 3. 2014
2. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516
3. Kim DD, Eng C (2012) The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012:406830
4. Grothey A, Van Cutsem E, Sobrero A, CORRECT Study Group et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet 381(9863):303–312
5. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G et al (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti- tumor activity. Int J Cancer 129:245–255
6. Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2(1):51–63
7. Benson AB 3rd, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926
8. Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD (2014) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist 19:669–680
9. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667
10. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H et al (2014) Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Investig New Drugs 32:104–112